Oct. 18, 2022

Why Clinical Trial Enrollment Sucks

Why Clinical Trial Enrollment Sucks

My guest today is Dr. Selin Kurnaz, Founder and CEO of Massive Bio, a company that is as impressive as it sounds. Its mission is to solve one of the single most critical scathing holes in healthcare: the "last mile" of clinical trial enrollment. What does that mean? You'll find out during our conversation, and rightfully so; the explanation will further deepen your pre-existing disdain for "the system." Selin is a no-BS serial entrepreneur who defines herself as a "non-status-quo businesswoman." whose sole purpose is to ensure every cancer patient gets access to a clinical trial; because only 20% of all patients that qualify for a clinical trial never actually fully enroll in that trial. And that is not OK. All that and more on the show today, let's get started.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Apple Podcasts podcast player iconSpotify podcast player iconYouTube podcast player iconPodcast Addict podcast player iconCastbox podcast player iconPocketCasts podcast player iconiHeartRadio podcast player iconRSS Feed podcast player icon
Apple Podcasts podcast player iconSpotify podcast player iconYouTube podcast player iconPodcast Addict podcast player iconCastbox podcast player iconPocketCasts podcast player iconiHeartRadio podcast player iconRSS Feed podcast player icon

My guest today is Dr. Selin Kurnaz, Founder and CEO of Massive Bio, a company that is as impressive as it sounds. Its mission is to solve one of the single most critical scathing holes in healthcare: the "last mile" of clinical trial enrollment. What does that mean? You'll find out during our conversation, and rightfully so; the explanation will further deepen your pre-existing disdain for "the system." Selin is a no-BS serial entrepreneur who defines herself as a "non-status-quo businesswoman." whose sole purpose is to ensure every cancer patient gets access to a clinical trial; because only 20% of all patients that qualify for a clinical trial never actually fully enroll in that trial. And that is not OK. All that and more on the show today, let's get started.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.